<DOC>
	<DOCNO>NCT01849094</DOCNO>
	<brief_summary>To determine pharmacokinetic profile new ( extended release ) formulation milrinone demonstrate evidence hemodynamic effect Primary : Pharmacokinetic profile - demonstrate stable plasma level Secondary ( HF cohort ) - demonstrate evidence haemodynamic benefit Study Design : Open label</brief_summary>
	<brief_title>Evaluating Safety , Pharmacokinetics Haemodynamic Effect Slow Release Oral Formulation Milrinone</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Milrinone</mesh_term>
	<criteria>Part A : Healthy volunteer ; Part B : Heart failure patient Inclusion Criteria Part A Healthy Volunteers Participants must : 1 . Provide write informed consent prior study procedure agree adhere protocol requirement 2 . Be age 18 45 year old inclusive time consent 3 . Be good general health without clinically significant medical history 4 . Have body mass index ( BMI ) 19 30 kg/m2 inclusive 5 . Documented 12lead ECG clinically significant abnormality , determine Investigator 6 . No clinically significant abnormality screen Day 0 laboratory test , determine Investigator ; 7 . Female subject reproductive potential must negative serum pregnancy ( Î²HCG ) test screen negative urine pregnancy test Day 0 prior dose . Female subject must also nonlactating 8 . Negative Human Immunodeficiency Virus ( HIV ) , Hepatitis B Hepatitis C Screening test result Inclusion Criteria Part B Heart Failure Patients Participants must : 1 . Provide write informed consent prior study procedure agree adhere protocol requirement 2 . Heart Failure patient LVEF le than45 % 3 . NYHA IIIII 4 . Stable medication ( great 48hrs ) 5 . Systolic BP great 90 Exclusion Criteria Part A Healthy Volunteers Participants enrol meet follow criterion : 1 . If female , pregnant lactate 2 . Receipt investigational agent drug within 30 day 5 halflives ( whichever longer ) prior first dose Investigational product 3 . Use prescription drug within 4 week prior first dose . Subjects use counter medication exclude paracetamol , topical counter medication routine vitamin include megadose ( intake 20 600 time recommended daily dose ) vitamin therapy within 7 day first dose , unless agree nonclinically relevant Principal Investigator 4 . No clinically relevant finding medical history , laboratory examination physical examination , especially regard cardiovascular system renal function 5 . A positive urine test drug abuse alcohol Screening day admittance Study Unit 6 . Normal dietary habit 7 . Any major surgical procedure within one month entry study 8 . Have difficulty communicate reliably Investigator unlikely cooperate requirement study . 9 . Any condition view Investigator likely interfere study put subject risk . Exclusion Criteria Part B Heart Failure Patients 1 . Unstable heart failure include NYHA IV symptoms 2 . Treatment intravenous inotropes mechanical circulatory support . 3 . Unstable rhythm include frequent nonsustained ventricular tachycardia poorly control atrial fibrillation ( ventricular rate &gt; 100 ) . 4 . Severe renal impairment Cr &gt; 200umol/L dialysis . 5 . Lifethreatening haematological , hepatic pulmonary disease .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>